Stay updated on Durvalumab & Tremelimumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab & Tremelimumab in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    A site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.
    Difference
    1%
    Check dated 2026-10-26T11:22:00.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the study page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-19T12:14:57.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T14:48:20.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    A new Revision: v3.7.0 is shown, and several key study documents and contact/resources have been redacted or removed from the Study Documents section, reducing access to the SAP, CSP, and related materials.
    Difference
    17%
    Check dated 2026-09-21T22:25:52.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Tel Litwinsky, Israel, 52621 was added as a study site. Qiryat Krinitzi, Israel, 52621 was removed from the participating locations.
    Difference
    0.0%
    Check dated 2026-09-14T20:06:45.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The study locations were updated by adding Qiryat Krinitzi, Israel, 52621 and removing Tel Litwinsky, Israel, 52621; the page revision was updated from v3.6.5 to v3.6.6.
    Difference
    0.0%
    Check dated 2026-08-31T18:30:07.000Z thumbnail image

Stay in the know with updates to Durvalumab & Tremelimumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelimumab in NSCLC Clinical Trial page.